- Home
- CHN vs ACHV Comparison
CHN vs ACHV Comparison
Compare CHN & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- ACHV
- Stock Information
- Founded
- CHN 1992
- ACHV N/A
- Country
- CHN United States
- ACHV United States
- Employees
- CHN N/A
- ACHV N/A
- Industry
- CHN Investment Managers
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CHN Finance
- ACHV Health Care
- Exchange
- CHN Nasdaq
- ACHV Nasdaq
- Market Cap
- CHN 153.9M
- ACHV 131.2M
- IPO Year
- CHN N/A
- ACHV N/A
- Fundamental
- Price
- CHN $15.87
- ACHV $2.50
- Analyst Decision
- CHN
- ACHV Strong Buy
- Analyst Count
- CHN 0
- ACHV 3
- Target Price
- CHN N/A
- ACHV $14.33
- AVG Volume (30 Days)
- CHN 31.8K
- ACHV 1.2M
- Earning Date
- CHN 01-01-0001
- ACHV 08-07-2025
- Dividend Yield
- CHN 0.19%
- ACHV N/A
- EPS Growth
- CHN N/A
- ACHV N/A
- EPS
- CHN N/A
- ACHV N/A
- Revenue
- CHN N/A
- ACHV N/A
- Revenue This Year
- CHN N/A
- ACHV N/A
- Revenue Next Year
- CHN N/A
- ACHV N/A
- P/E Ratio
- CHN N/A
- ACHV N/A
- Revenue Growth
- CHN N/A
- ACHV N/A
- 52 Week Low
- CHN $9.00
- ACHV $1.84
- 52 Week High
- CHN $12.98
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- CHN 64.58
- ACHV 42.75
- Support Level
- CHN $15.40
- ACHV $2.52
- Resistance Level
- CHN $16.06
- ACHV $2.75
- Average True Range (ATR)
- CHN 0.20
- ACHV 0.12
- MACD
- CHN -0.07
- ACHV 0.01
- Stochastic Oscillator
- CHN 46.53
- ACHV 6.61
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.